Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$6.82 – $7.04
Volume21,419
Market cap$54M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$53.59M
Price / earnings
—
Price / book
-35×
Price / sales
232×
EV / sales
168.93×
EV / EBITDA
-1.69×
Profitability
Earnings per share
-$3.35
Return on assets
-135.45%
Return on equity
1,694.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
1.21×
Quick ratio
1.1×
Cash ratio
1.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for COCH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$66K
$51K
$39K
$75K
$42K
$78K
$46K
$42K
Cost of revenue
$244K
$278K
$313K
$211K
$203K
$234K
$226K
$157K
Gross profit
-$178K
-$227K
-$274K
-$136K
-$161K
-$156K
-$180K
-$115K
Selling, general and administrative
$2.28M
$2.21M
$2.04M
$1.7M
$2.4M
$2.43M
$2.18M
$1.96M
Research and development
$3.08M
$3.13M
$3.64M
$4.55M
$2.7M
$2.49M
$2.75M
$2.47M
Total operating expenses
$5.36M
$5.34M
$5.69M
$6.25M
$5.1M
$4.91M
$4.93M
$4.43M
Operating income
-$5.54M
-$5.57M
-$5.96M
-$6.39M
-$5.27M
-$5.07M
-$5.11M
-$4.55M
Interest expense
$0
$0
$0
$0
-$471K
-$624K
-$495K
-$384K
Income before taxes
-$3.93M
-$5.98M
-$4.35M
-$6.59M
-$6.48M
-$5.69M
-$5M
-$4.62M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.93M
-$5.98M
-$4.35M
-$6.59M
-$6.48M
-$5.69M
-$5M
-$4.62M
Net income attributable to common shareholders
-$5.24M
-$7.27M
-$5.7M
-$7.74M
-$7.75M
-$6.94M
-$6.24M
-$7.69M
EBITDA
-$5.46M
-$5.5M
-$5.89M
-$6.31M
-$5.19M
-$4.99M
-$5.05M
-$4.5M
Basic earnings per share
-$0.50
-$0.70
-$0.80
-$2.72
-$3.55
-$3.20
-$2.90
-$3.97
Diluted earnings per share
-$0.50
-$0.70
-$0.80
-$2.72
-$3.55
-$3.20
-$2.90
-$3.97
Recent news
Company coverage with links to the original publishers.
Sight Sciences (SGHT) reported a quarterly loss of $0.12 per share matching consensus estimates, with revenues of $24.92 million exceeding expectations by 6.46%. The company has outperformed the market by 18.8% year-to-date but received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.
EdgarAgents, a leading provider of SEC compliance filing solutions, has launched EA34 Plugin, a technology-enabled platform that simplifies the financial reporting process for mid-to-microcap companies. The plugin eliminates the complex XBRL tagging process and enables intuitive collaboration through Microsoft 365 apps.
Envoy Medical received FDA approval to initiate a pivotal clinical study for its Acclaim Fully Implanted Cochlear Implant, a breakthrough hearing device that leverages the natural anatomy of the ear to capture sound.
WHITE BEAR LAKE, MN, June 06, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index. The inclusion became effective at the close of market on Friday, May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance of the micro cap segment of the U.S. equity market and is comprised of over 1,100 constituents with an average market cap of $122 million at April 30, 2024. A wide range of microcap ETFs follow this benchmark and may reweight their holdings over the coming weeks for changes that occurred in this Index effective as of May 31.
The Company, a current leader in fully implanted hearing devices, continues to steadily march towards its ambition of disrupting the existing cochlear implant industry with its “breakthrough” fully implanted cochlear implant.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.